Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 208: MVA-EbolaZ Vaccine Study
NCT02408913Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2015
- Primary completion
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVA-EbolaZ in Ebola virus disease (EVD) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local and systemic reactogenicity signs and symptoms at 7 days, Occurrence of adverse events of all severities at 4 weeks and 1 more. Started Mar 2015; status: completed.
02
Drugs
MVA-EbolaZ
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02408913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408913.